Insider Selling: Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) SVP Sells 10,000 Shares of Stock

Key Points

• Mirum Pharmaceuticals SVP Jolanda Howe sold 10,000 shares at an average price of $58, totaling $580,000, which reduced her ownership by 80.48%.
• For Q2, Mirum Pharmaceuticals reported a 64.1% increase in revenue to $127.79 million, surpassing expectations, and it beat earnings per share estimates by $0.19.
• Several analysts have provided varying ratings, with one institution issuing a "strong-buy" rating while others downgraded the stock, highlighting mixed sentiment among market experts.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Get Free Report) SVP Jolanda Howe sold 10,000 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $58.00, for a total transaction of $580,000.00. Following the sale, the senior vice president owned 2,426 shares in the company, valued at approximately $140,708. This trade represents a 80.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Jolanda Howe also recently made the following trade(s):

• On Thursday, July 3rd, Jolanda Howe sold 477 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $49.08, for a total transaction of $23,411.16.
• On Wednesday, July 2nd, Jolanda Howe sold 564 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $48.25, for a total transaction of $27,213.00.

Mirum Pharmaceuticals Trading Up 1.7%

Mirum Pharmaceuticals stock traded up $1.08 during midday trading on Wednesday, reaching $65.80. The stock had a trading volume of 296,403 shares, compared to its average volume of 488,990. The firm's fifty day simple moving average is $51.65 and its two-hundred day simple moving average is $47.42. Mirum Pharmaceuticals, Inc. has a twelve month low of $36.86 and a twelve month high of $67.45. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.13 and a quick ratio of 2.97. The firm has a market cap of $3.31 billion, a price-to-earnings ratio of -54.45 and a beta of 0.94.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.31) by $0.19. The company had revenue of $127.79 million during the quarter, compared to analyst estimates of $107.91 million. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The company's revenue for the quarter was up 64.1% on a year-over-year basis. During the same quarter last year, the business posted ($0.52) EPS. Equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on MIRM. Stifel Nicolaus set a $89.00 price target on shares of Mirum Pharmaceuticals and gave the company a "buy" rating in a research note on Monday. Raymond James Financial restated a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research note on Thursday, August 7th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday. JMP Securities set a $81.00 price target on shares of Mirum Pharmaceuticals and gave the company a "market outperform" rating in a research note on Thursday, August 7th. Finally, HC Wainwright raised their price target on shares of Mirum Pharmaceuticals from $73.00 to $80.00 and gave the company a "buy" rating in a research note on Thursday, August 7th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of "Buy" and an average price target of $74.13.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. CWM LLC raised its holdings in Mirum Pharmaceuticals by 259.4% in the 1st quarter. CWM LLC now owns 593 shares of the company's stock worth $27,000 after acquiring an additional 428 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new position in Mirum Pharmaceuticals in the 4th quarter worth $35,000. Comerica Bank raised its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company's stock worth $40,000 after acquiring an additional 278 shares during the period. GF Fund Management CO. LTD. bought a new position in Mirum Pharmaceuticals in the 4th quarter worth $42,000. Finally, Quarry LP bought a new position in Mirum Pharmaceuticals in the 1st quarter worth $56,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.